Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03014687 · ClinicalTrials.gov registry record · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
A Phase 4 study of Pituitary Adenoma and Antibiotics, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT03014687: Recruiting Phase 4 study of Pituitary Adenoma and Antibiotics, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
NCT03014687 is a Phase 4 study of Pituitary Adenoma and Antibiotics that is actively recruiting participants, run by St. Joseph's Hospital and Medical Center, Phoenix. The registered enrollment target is 116 participants, below the 276-participant average among 9 other Pituitary Adenoma trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03014687, a Phase 4 study of Pituitary Adenoma and Antibiotics, is actively recruiting participants, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
To find out whether oral antibiotics given after transsphenoidal endoscopic surgery for pituitary adenoma improves sinus and nasal symptoms, reduces the incidence of infection (sinusitis), and helps mucosal healing in the nasal passages.
Primary Outcome
Completed by subject in clinic or by phone interview. Assesses urge to blow nose; post-nasal discharge; thick nasal discharge; headaches; nose makes whistling sound; nasal crusting; trouble breathing through nose during day; trouble breathing through nose during night; not breathing equally in both nostrils; sense of smell; sense of taste; and, overall functioning of nose.Rating choices include no problem 0; very minor problem 1; minor problem 2; moderate problem 3; moderately severe problem 4;
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
Study Locations (1)
Arizona
- Barrow Brain and Spine - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2019-07 |
| Phase | Phase 4 |
What NCT03014687 shows while recruiting
NCT03014687 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 276-participant average among 9 other Pituitary Adenoma trials with a reported enrollment target (58% lower).
The record links to 2 conditions, with Pituitary Adenoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03014687 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT03014687 about?
NCT03014687 is a clinical study titled "Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions". To find out whether oral antibiotics given after transsphenoidal endoscopic surgery for pituitary adenoma improves sinus and nasal symptoms, reduces the incidence of infection (sinusitis), and helps mucosal healing in the nasal passages.
What is the current status of trial NCT03014687?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 116 participants. The study started on 2017-07-01. Estimated completion is 2019-07.
What conditions does trial NCT03014687 study?
This clinical trial studies the following conditions: Pituitary Adenoma, Antibiotics.
What interventions are being tested in trial NCT03014687?
The interventions under investigation include: Placebo (DRUG), Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole (DRUG).
Who is sponsoring clinical trial NCT03014687?
This trial is sponsored by St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03014687 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pituitary Adenoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03014687's enrollment target sits among peer trials
116 5th of 9 higher than 5 of 9 other Pituitary Adenoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pituitary Adenoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
RECRUITING · Phase 4
-
Surgical Debulking of Pituitary Adenomas
COMPLETED · Phase 4
-
Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
RECRUITING
-
DDAVP for Pituitary Adenoma
RECRUITING · NA
-
Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
RECRUITING · Phase 1
-
A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
- NCT04372615 · 116 participants · Phase 2
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI